CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 3,442,996 enrolled
Drug / intervention
Comirnaty +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05858450
NCT05858450N/ACompleted
CompareCT.gov

Investigating Uptake and Subsequent Health Outcomes Associated With Pfizer-BioNTech Bivalent COVID-19/Influenza Vaccine Concomitant Administration Using a Claims-based Real-world Data Source in the US

Pfizer·observational·Posted May 15, 2023·Updated Sep 20, 2024

In Brief

An observational study evaluating Comirnaty and Quadrivalent Influenza Vaccine for Influenza, Human and COVID-19. Completed, enrolled 3,442,996 participants across 1 site.

Detailed Summary

This study intends to describe the characteristics of patients given the Pfizer-BioNTech bivalent mRNA COVID-19 vaccine and any commercially available influenza vaccines at the same time versus at different times.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza, Human, COVID-19
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
202420252026
First PostedMay 15, 2023
Enrollment StartMay 5, 2023
Primary CompletionMay 12, 2023
TodayJul 2, 2026
Enrollment to primary: 7 daysPosted 3.1 years ago

Interventions

Comirnatybiological

COMIRNATY is an active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older.

Quadrivalent Influenza Vaccinebiological

Quadrivalent Influenza Vaccine is a class of vaccines indicated for active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccines